Roche, PTC Research Muscular Atrophy | Chemical & Engineering News
Volume 89 Issue 49 | p. 21 | Concentrates
Issue Date: December 5, 2011

Roche, PTC Research Muscular Atrophy

Department: Business
Keywords: spinal muscular atrophy, drug discovery

Roche has licensed rights to PTC Therapeutics’ drug discovery program in spinal muscular atrophy, a genetic disorder that causes muscle weakness. Roche will pay $30 million for the program, which includes three small molecules currently in preclinical development. The Swiss firm could also make up to $460 million in milestone payments. PTC developed the program in partnership with the SMA Foundation, which will remain active in the collaboration.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment